Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1615 studies found for:    "Myelodysplastic syndromes"
Show Display Options
Download search resultsDownload the search results for:
"Myelodysplastic syndromes" (1615 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Unknown  Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Intervention: Drug: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
2 Terminated
Has Results
Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Clofarabine
3 Completed Clofarabine in High Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Intervention: Drug: Clofarabine
4 Completed A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Drug: Darbepoetin Alfa
5 Not yet recruiting A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Omacetaxine;   Drug: Azacitidine;   Drug: G-CSF
6 Active, not recruiting Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: decitabine;   Drug: tretinoin;   Genetic: DNA methylation analysis;   Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
7 Completed Erlotinib in Higher Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Erlotinib
8 Recruiting Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: DSP-7888
9 Unknown  Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Darbepoetin
10 Completed Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide, Decitabine
11 No longer available An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: decitabine
12 Completed
Has Results
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid
13 Terminated
Has Results
RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: everolimus;   Other: laboratory biomarker analysis;   Procedure: Bone marrow aspirate/biopsy
14 Terminated A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts
Condition: Myelodysplastic Syndromes
Intervention: Drug: BEVACIZUMAB
15 Recruiting Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Biological: MEDI4736 Evaluate MEDI4736 in MDS;   Drug: VIDAZA;   Biological: tremelimumab
16 Unknown  Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Intervention: Drug: DN-101 (calcitriol)
17 Completed Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na
18 Active, not recruiting Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndrome
Interventions: Drug: Decitabine;   Drug: Vorinostat;   Biological: Interleukin-2;   Other: Natural killer (NK) cells
19 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
20 Completed
Has Results
An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Azacitidine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.